Cover Image
市場調查報告書

乾癬性關節炎:開發中產品分析

Psoriatic Arthritis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232834
出版日期 內容資訊 英文 231 Pages
訂單完成後即時交付
價格
Back to Top
乾癬性關節炎:開發中產品分析 Psoriatic Arthritis - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 231 Pages
簡介

乾癬性關節炎(PA)是罹患乾癬的人部份合併發作的關節炎。常見的症狀有手、腳指腫、腳部疼痛、腰痛等。致病因子有年齡、家族病史、乾癬患者等。治療方法包含NSAID(非類固醇消炎劑),免疫抑制劑,外科手術等。

本報告提供乾癬性關節炎的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

乾癬性關節炎概要

治療藥的開發

  • 開發中產品的概要

乾癬性關節炎:企業開發中的治療藥

乾癬性關節炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

乾癬性關節炎:企業開發中的產品

乾癬性關節炎的治療藥開發企業

  • AbbVie Inc.
  • AbGenomics International, Inc.
  • Alder Biopharmaceuticals Inc.
  • Alteogen Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • BIOCAD
  • Biocon Limited
  • Bionovis SA
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celltrion, Inc.
  • Coherus BioSciences, Inc.
  • Eli Lilly and Company
  • Epirus Biopharmaceuticals, Inc.
  • Forward Pharma A/S
  • Genor BioPharma Co., Ltd.
  • Innovent Biologics, Inc.
  • Johnson & Johnson
  • Kadmon Corporation, LLC
  • Kineta, Inc.
  • Mabion SA
  • Momenta Pharmaceuticals, Inc.
  • Morphotek, Inc.
  • Mycenax Biotech Inc.
  • Novo Nordisk A/S
  • Oncobiologics, Inc.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sandoz International GmbH
  • Swedish Orphan Biovitrum AB
  • Therapeutic Proteins International, LLC
  • UCB S.A.
  • Valeant Pharmaceuticals International, Inc.
  • Vitae Pharmaceuticals, Inc.
  • Xbrane Biopharma AB

乾癬性關節炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

乾癬性關節炎:最近的開發平台趨勢

乾癬性關節炎:暫停中的計劃

乾癬性關節炎:開發中止的產品

乾癬性關節炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8680IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Pipeline Review, H2 2016, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 9, 8, 10, 2, 15, 7 and 2 respectively.Psoriatic Arthritis.

Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Psoriatic Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Psoriatic Arthritis Overview
  • Therapeutics Development
    • Pipeline Products for Psoriatic Arthritis - Overview
    • Pipeline Products for Psoriatic Arthritis - Comparative Analysis
  • Psoriatic Arthritis - Therapeutics under Development by Companies
  • Psoriatic Arthritis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Psoriatic Arthritis - Products under Development by Companies
  • Psoriatic Arthritis - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • AbbVie Inc
    • AbGenomics International, Inc.
    • Alteogen Inc.
    • Amgen Inc.
    • Biocon Limited
    • Bionovis SA
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Coherus BioSciences, Inc.
    • Eli Lilly and Company
    • Forward Pharma A/S
    • Genor BioPharma Co Ltd
    • Innovent Biologics, Inc.
    • Johnson & Johnson
    • Kadmon Corporation, LLC
    • KPI Therapeutics, Inc.
    • Momenta Pharmaceuticals, Inc.
    • Morphotek, Inc.
    • Mycenax Biotech Inc.
    • NeuClone Pty Ltd
    • Novo Nordisk A/S
    • Oncobiologics, Inc.
    • Pfizer Inc.
    • Prothena Corporation Plc
    • Reliance Life Sciences Pvt. Ltd.
    • Sandoz International GmbH
    • Therapeutic Proteins International, LLC
    • UCB SA
    • Valeant Pharmaceuticals International, Inc.
    • Vitae Pharmaceuticals, Inc.
    • Vitaeris Inc
    • Xbrane Biopharma AB
  • Psoriatic Arthritis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abatacept - Drug Profile
    • AbGn-168H - Drug Profile
    • ABT-122 - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • apremilast - Drug Profile
    • apremilast - Drug Profile
    • bimekizumab - Drug Profile
    • certolizumab pegol biosimilar - Drug Profile
    • clazakizumab - Drug Profile
    • dalazatide - Drug Profile
    • dimethyl fumarate - Drug Profile
    • DNX-114 - Drug Profile
    • DNX-514 - Drug Profile
    • Drug to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile
    • etanercept - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • golimumab - Drug Profile
    • golimumab biosimilar - Drug Profile
    • golimumab biosimilar - Drug Profile
    • guselkumab - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • INV-17 - Drug Profile
    • itolizumab - Drug Profile
    • ixekizumab - Drug Profile
    • KANAb-071 - Drug Profile
    • KD-025 - Drug Profile
    • liraglutide - Drug Profile
    • PRX-003 - Drug Profile
    • risankizumab - Drug Profile
    • tofacitinib citrate - Drug Profile
    • upadacitinib tartrate - Drug Profile
    • ustekinumab biosimilar - Drug Profile
    • ustekinumab biosimilar - Drug Profile
    • VALBRO-03 - Drug Profile
    • VTP-43742 - Drug Profile
  • Psoriatic Arthritis - Dormant Projects
  • Psoriatic Arthritis - Discontinued Products
  • Psoriatic Arthritis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Psoriatic Arthritis, H2 2016
  • Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Psoriatic Arthritis - Pipeline by 3SBio Inc., H2 2016
  • Psoriatic Arthritis - Pipeline by AbbVie Inc, H2 2016
  • Psoriatic Arthritis - Pipeline by AbGenomics International, Inc., H2 2016
  • Psoriatic Arthritis - Pipeline by Alteogen Inc., H2 2016
  • Psoriatic Arthritis - Pipeline by Amgen Inc., H2 2016
  • Psoriatic Arthritis - Pipeline by Biocon Limited, H2 2016
  • Psoriatic Arthritis - Pipeline by Bionovis SA, H2 2016
  • Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Psoriatic Arthritis - Pipeline by Celgene Corporation, H2 2016
  • Psoriatic Arthritis - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H2 2016
  • Psoriatic Arthritis - Pipeline by Forward Pharma A/S, H2 2016
  • Psoriatic Arthritis - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • Psoriatic Arthritis - Pipeline by Innovent Biologics, Inc., H2 2016
  • Psoriatic Arthritis - Pipeline by Johnson & Johnson, H2 2016
  • Psoriatic Arthritis - Pipeline by Kadmon Corporation, LLC, H2 2016
  • Psoriatic Arthritis - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Psoriatic Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
  • Psoriatic Arthritis - Pipeline by Morphotek, Inc., H2 2016
  • Psoriatic Arthritis - Pipeline by Mycenax Biotech Inc., H2 2016
  • Psoriatic Arthritis - Pipeline by NeuClone Pty Ltd, H2 2016
  • Psoriatic Arthritis - Pipeline by Novo Nordisk A/S, H2 2016
  • Psoriatic Arthritis - Pipeline by Oncobiologics, Inc., H2 2016
  • Psoriatic Arthritis - Pipeline by Pfizer Inc., H2 2016
  • Psoriatic Arthritis - Pipeline by Prothena Corporation Plc, H2 2016
  • Psoriatic Arthritis - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016
  • Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H2 2016
  • Psoriatic Arthritis - Pipeline by Therapeutic Proteins International, LLC, H2 2016
  • Psoriatic Arthritis - Pipeline by UCB SA, H2 2016
  • Psoriatic Arthritis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
  • Psoriatic Arthritis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016
  • Psoriatic Arthritis - Pipeline by Vitaeris Inc, H2 2016
  • Psoriatic Arthritis - Pipeline by Xbrane Biopharma AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Psoriatic Arthritis - Dormant Projects, H2 2016
  • Psoriatic Arthritis - Dormant Projects (Contd..1), H2 2016
  • Psoriatic Arthritis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Psoriatic Arthritis, H2 2016
  • Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top